GuruFocus
13 Jun 2026, 16:00 UTC · 12h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Top 1 mover · tap to explore
What the story claims
1 claim · each scored for market impact
Eli Lilly (NYSE: LLY) will present initial clinical data for its first-in-class type II JAK2 inhibitor for treated myelofibrosis at the 2026 EHA Annual Meeting. — Positive clinical data for a first-in-class drug in a specific therapeutic area typically acts as a catalyst for stock price appreciation.
+0.40Which stocks this story touches
The company is presenting new clinical data for a first-in-class inhibitor, which is generally a positive development for a pharmaceutical pipeline.
Continue reading
6 related stories
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
13h ago
